Rice Hall James & Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rice Hall James & Associates’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.13M	Buy	167,766 +40,301	+32%	+$668K	0.17%	126
2025 Q4	$1.68M	Sell	127,465 -7,370	-5%	-$87K	0.09%	173
2025 Q3	$967K	Sell	134,835 -7,485	-5%	-$390K	0.05%	206
2025 Q2	$6.72M	Buy	142,320 +4,804	+3%	+$196K	0.36%	69
2025 Q1	$5.37M	Buy	137,516 +26,383	+24%	+$1.14M	0.32%	69
2024 Q4	$6.02M	Buy	111,133 +35,664	+47%	+$1.82M	0.33%	69
2024 Q3	$3.81M	Buy	+75,469	New	+$3.54M	0.21%	110

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rice Hall James & Associates's MLTX Position: Q1 2026 in Review

Rice Hall James & Associates increased its MoonLake Immunotherapeutics (MLTX) stake by 32% in Q1 2026, buying an estimated $668K and bringing the position to 167,766 shares worth $3.13M. The position accounts for 0.17% of the portfolio, ranked #126.

Rice Hall James & Associates first reported a position in MLTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $6.72M in Q2 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Rice Hall James & Associates held 167,766 shares of MoonLake Immunotherapeutics worth $3.13M as of Q1 2026.
Rice Hall James & Associates bought 40,301 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $668K.
MoonLake Immunotherapeutics made up 0.17% of Rice Hall James & Associates's portfolio in Q1 2026, its #126 holding.
Rice Hall James & Associates first reported a position in MoonLake Immunotherapeutics in Q3 2024 and has held it in 7 quarters since.
Rice Hall James & Associates's MoonLake Immunotherapeutics position peaked at $6.72M in Q2 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.